AORT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Artivion Inc (AORT) is not a good buy right now for a beginner long-term investor, especially one who is impatient and wants to deploy $50,000-$100,000 without waiting for a better entry. The business has solid revenue growth and Wall Street remains constructive, but the stock is currently technically weak, options sentiment is cautious-bullish but thin, and the latest financials show profitability pressure. My direct view: hold off for now rather than buy immediately.
The trend is bearish in the near term. MACD histogram is negative and still contracting, RSI_6 at 44.17 is neutral but below strong momentum levels, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Price closed at 30.75, which is below the pivot of 36.10 and also below S1 at 34.54, showing continued weakness. The stock trend model suggests only modest upside over the next week/month, with a 70% chance of a small next-day decline. Overall, the technical picture does not support an immediate long-term entry.
["Needham added Artivion to its Conviction List and kept a Buy rating with a $58 target.", "Ladenburg upgraded the stock to Buy with a $42 target.", "Analysts see a product-cycle boost from AMDS, with NEXUS expected to add another catalyst.", "Revenue in 2025/Q4 grew 19.20% YoY, showing strong top-line expansion.", "Wall Street expects continued low-teens or better organic revenue growth and 20%+ EBITDA growth."]
["No news in the recent week, so there is no fresh event-driven catalyst right now.", "The stock closed sharply lower versus the previous close, showing weak near-term momentum.", "Net income fell 114.73% YoY in 2025/Q4, indicating profitability deterioration.", "EPS dropped 112.82% YoY, which is a negative quality signal despite revenue growth.", "Gross margin slipped slightly YoY.", "Hedge funds and insiders are both neutral, with no notable accumulation trend.", "No recent congress trading data is available.", "Post-market move was sharply negative at -13.18%, which adds caution to the near-term setup."]
In the latest reported quarter, 2025/Q4, Artivion posted revenue of $115.99M, up 19.20% YoY, which is a strong growth trend. However, profitability weakened materially: net income fell to $2.42M, down 114.73% YoY, and EPS declined to $0.05, down 112.82% YoY. Gross margin was 63.06%, slightly down 0.22% YoY. The latest quarter shows good sales growth but weak earnings conversion, so the business is growing but not yet translating that growth into strong bottom-line momentum.
Wall Street sentiment is positive overall. Needham added AORT to its Conviction List and maintained Buy with a $58 target, citing the AMDS product cycle and upcoming NEXUS launch. Ladenburg upgraded the stock to Buy from Neutral with a $42 target. Canaccord also kept Buy, though it trimmed its target to $48 from $51 after a strong quarter that was partly obscured by a one-time revenue reduction. The pros view is constructive on growth and pipeline catalysts, but the recent target cut shows some caution around near-term execution and earnings quality.
